ClearPoint Neuro announced it has received 510(k) clearance for its SmartFrame OR Stereotactic System. “Expanding ClearPoint’s portfolio beyond the MRI into the operating room is of key strategic significance to the Company in 2024 and beyond,” stated Joe Burnett, President and CEO at ClearPoint Neuro. “More than 95% of all stereotactic neuro-navigation procedures take place in the OR, supporting DBS, Laser Ablation, Biopsy, sEEG, and more. This product is the first in ClearPoint’s history that does not require the use of MRI during the procedure, allowing us to access more hospitals, and to support an order of magnitude more patients than our legacy portfolio. Importantly, the SmartFrame OR is compatible with capital hardware and software already present in many neurosurgical operating rooms and should not require the approval by hospital capital committees for surgeons to try this new product.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on CLPT:
- ClearPoint Neuro sees FDA clearance and launch SmartFrame OR in 2024
- ClearPoint Neuro sees FY24 revenue $28M-$32M, consensus $30.43M
- ClearPoint Neuro seesFY24 revenue $28M-$32M, consensus $30.4M
- ClearPoint Neuro sees FY23 revenue $24M, consensus $23.37M
- ClearPoint Neuro raises Q4 revenue view to $6.8M from $6.22M, consensus $6.69M